Agenus Q2 net loss $54.8M, advances BOT/BAL in CRC; appoints director; files ATM for up to 13.8M shares

AGENUS INC

2024-Q2 EPS reported -$5.56 revenue$51,514,000

Q2 net loss $54.8M, revenue $23.5M (incl $22.6M non-cash royalty); cash $93.7M at June 30 vs $76.1M Dec 31.
BOT/BAL in r/r MSS CRC: RECIST ORR 19.4% in selected cohort; 90% 6-month OS; FDA discouraged AA submission; plan to refile with mature data.
NEST-2 neoadjuvant CRC: 56% (5/9) patients achieved complete pathologic responses; 78% had ≥50% tumor reduction.
Appointed Thomas L. Harrison to Board as Class III director; granted option for 7,500 shares vesting over 3 years.
Filed prospectus supplement for ATM offering of up to 13,843,015 shares under existing B. Riley sales agreement.

item 2.02 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Thomas L. Harrison

Class III director

AGEN · AGENUS INC

Effective: 2024-08-07
Filed: August 8, 2024, 7:59 PM ET

On August 7, 2024, the Board of Directors (the “Board”) of Agenus elected Thomas L. Harrison to become a Class III director of Agenus with an initial term that expires at Agenus’s annual meeting of stockholders in 2027.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas L. Harrison was elected as Class III director at AGENUS INC.

Action: elected
Role: Class III director

Exact text from the filing

On August 7, 2024, the Board of Directors (the “Board”) of Agenus elected Thomas L. Harrison to become a Class III director of Agenus with an initial term that expires at Agenus’s annual meeting of stockholders in 2027.

View on SEC.gov

AGENUS INC filing history →

Source: SEC EDGAR

accession 0001193125-24-197046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.